ViatrisHAM:VIA +1.71%58 Median PS Value is €9.80 as of Jun. 26, 2026, which is 100% below its 10-year median of 0.73. GuruFocus rates HAM:VIA with a GF Score™ of 58/100 and a GF Value™ of €9.77 (Significantly Overvalued). The stock has 7 warning signs investors should review. Among 544 Drug Manufacturers companies, Viatris ranks worse than 83.46% on this metric.
This valuation method assumes that the stock valuation will revert to its historical (10-Year) median in terms of PS Ratio. The reason we use PS Ratio instead of PE Ratio or PB Ratio is because PS Ratio is independent of profit margin, and can be applied to a broader range of situations.
Median PS Value is calculated as trailing twelve months (TTM) Revenue per Share times 10-Year median PS Ratio. Viatris's Revenue per Share for the trailing twelve months (TTM) ended in Mar. 2026 was €10.731. Viatris's 10-Year median PS Ratio is 0.9132. Therefore, the Median PS Value for today is €9.80.
As of today (2026-06-26), Viatris's share price is €14.256. Viatris's Median PS Value is €9.80. Therefore, Viatris's Price to Median PS Value for today is 1.45.
The historical rank and industry rank for Viatris's Median PS Value or its related term are showing as below:
HAM:VIA'
s Price-to-Median-PS-Value Range Over the Past 10 Years
Min: 0.35 Med: 0.73 Max: 1.45
Current: 1.45
During the past 13 years, the highest Price to Median PS Value of Viatris was 1.45. The lowest was 0.35. And the median was 0.73.
HAM:VIA's Price-to-Median-PS-Value is ranked worse than 83.46% of 544
companies
in the Drug Manufacturers industry
Industry Median: 0.83
vs HAM:VIA: 1.45
Viatris (HAM:VIA) Median PS Value Explanation
This valuation method assumes that the stock valuation will revert to its historical (10-Year) mean in terms of PS Ratio. The reason we use PS Ratio instead of PE Ratio or PB Ratio
is because PS Ratio is independent of profit margin, and can be applied to a broader range of situations.
It also assumes that over time the profit margin is constant. If a company increases its profit margin to a sustainable level, this value might under-estimate its value. If it has permanent declined profit margins, this may over-estimate the company's value.
Viatris's Price to Median PS Value for today is calculated as
Price to Median PS Value
=
Share Price
/
Median PS Value
=
14.256
/
9.80
=
1.45
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Viatris Median PS Value Related Terms
Viatris Median PS Value Historical Data
* Premium members only.
The historical data trend for Viatris's Median PS Value can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
HAM:VIA vs NBIX, UTHR, ELAN: Median PS Value Comparison
For the Drug Manufacturers - Specialty & Generic subindustry, Viatris's Price-to-Median-PS-Value, along with its competitors' market caps and Price-to-Median-PS-Value data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Viatris Price-to-Median-PS-Value vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Viatris's Price-to-Median-PS-Value distribution charts can be found below:
* The bar in red indicates where Viatris's Price-to-Median-PS-Value falls into.
10-Year Median PS Ratio is 0.9132.
Viatris's Revenue per Share for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was €10.731.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Viatris (HAM:VIA) has a Median PS Value of €9.80 as of Jun. 26, 2026. Median price-sales value is the stock value based on a company's 10-year median price-sales ratio, View historical data on Viatris and its competitors. This is 1242% above median its historical median of 0.73. Over the past decade, Viatris' Median PS Value has ranged from 0.35 to 1.45. According to the industry distribution chart, Viatris ranks #454 out of 544 companies in the Drug Manufacturers industry, placing it in the top 83.5%.
Is Viatris' Median PS Value too high?
Viatris' current Median PS Value of €9.80 is 1242% above median its 10-year median of 0.73. Over the past 10 years, this metric has ranged from a low of 0.35 to a high of 1.45. Based on the distribution chart, Viatris ranks #454 out of 544 companies in the Drug Manufacturers industry, which is in the bottom quartile relative to peers. Overall, Viatris has a GF Score™ of 58/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Viatris' Median PS Value compare to NBIX and UTHR?
According to the Drug Manufacturers industry distribution chart, Viatris ranks #454 out of 544 companies for Median PS Value. This places Viatris in the lower half of its industry. The industry median Median PS Value is 0.83. Historically, Viatris' own Median PS Value has ranged from 0.35 to 1.45 over the past decade. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Median PS Value for a Drug Manufacturers company?
The median Median PS Value among Drug Manufacturers companies is 0.83, based on 544 companies in the industry. Companies in the top quartile (top 25%) have a Median PS Value significantly above this median, while those in the bottom quartile fall well below. However, Median PS Value should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Median PS Value mean?
A high Median PS Value can signal that a stock is expensive relative to its fundamentals. Median price-sales value is the stock value based on a company's 10-year median price-sales ratio, View historical data on Viatris and its competitors. For the Drug Manufacturers industry, the median Median PS Value is 0.83 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Viatris's current Median PS Value is €9.80, which is 1242% above median its own 10-year median of 0.73. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Viatris stock overvalued right now?
Based on GuruFocus' analysis, Viatris (HAM:VIA) is currently considered Significantly Overvalued. The stock's GF Value™ is €9.77, compared to a current price of €14.26 — trading 45.9% above its estimated fair value. The current Median PS Value is €9.80, which is 1242% above median its 10-year median of 0.73. Viatris' overall GF Score™ is 58/100 with 7 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Median PS Value calculated?
Median PS Value is calculated from a company's financial statements. For Viatris (HAM:VIA), the current Median PS Value is €9.80 as of Jun. 26, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Viatris (HAM:VIA) Overvalued in 2026?
Based on GuruFocus' analysis, Viatris stock appears to be overvalued.
The current stock price of €14.26 is trading 45.9% above its estimated GF Value™ of €9.77.
GuruFocus considers Viatris to be Significantly Overvalued.
Key valuation signals for HAM:VIA:
Median PS Value: €9.80 (1242% above median its 10-year median of 0.73)
GF Value™: €9.77 vs. price of €14.26 (45.9% above fair value)
No single metric tells the full story. See the HAM:VIA stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Viatris was formed in November 2020 through the combination of Upjohn, a wholly owned subsidiary of Pfizer that specialized in off-patent drugs, and Mylan, a global pharmaceutical manufacturer that focused on generic and specialty drugs. By joining forces, Viatris became one of the largest generic drug manufacturers in the world, servicing over 165 countries. Generics (commoditized and complex) and biosimilars make up roughly 40% of Viatris' total sales. The remaining 60% of sales are derived from its portfolio of legacy products, which includes Lipitor, Norvasc, Lyrica, and Viagra. While it covers more than 10 major therapeutic areas, Viatris has identified dermatology, ophthalmology, and gastroenterology as its three key areas of focus for future innovations.
58GF Score
Get the complete analysis for HAM:VIA
Median PS Value is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
HAM:VIA has been successfully added to your 
